Business Context and Reporting Period
This Form 8-K Current Report was filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) on April 25, 2013. The report details an unregistered sale of equity securities to an accredited investor.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The specific financial activity reported is:
- Gross Proceeds: $150,000 from the sale of 600,000 units.
- Unit Price: $0.25 per unit.
- Unit Composition: One share of common stock plus a five-year warrant to purchase 50% of the shares purchased at an exercise price of $0.50.
- Additional Issuance: 1,000,000 shares of common stock issued to the investor as an inducement for the new investment and consideration for dilution.
- Broker-Dealer Compensation: A warrant to purchase up to 48,000 shares of common stock.
Material Changes
The primary material change is the increase in outstanding equity and potential future dilution due to the issuance of 600,000 units, 1,000,000 bonus shares, and associated warrants. The filing does not provide comparative period data for revenue or operating metrics.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of general business risks. Specific terms and risks related to the offering include:
- Exercise Limitations: Warrants cannot be exercised if the holder would beneficially own more than 4.99% of outstanding common stock, unless the holder provides 61 days' notice to increase the limit to 9.99%.
- Cashless Exercise: Warrants may be exercised on a cashless basis if no effective registration statement covers the resale of underlying shares.
- Regulatory Basis: Securities were sold under Section 4(2) and Regulation D (Rule 506) exemptions.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess the dilution impact of the 1,600,000+ new shares/warrants.
- Confirm the status of the registration statement for the resale of shares underlying the warrants.
- Review the full Subscription Agreement (Exhibit 10.1) and Warrant (Exhibit 10.2) for additional covenants or adjustment mechanisms.
- Check subsequent filings for the company's cash position following the $150,000 capital raise.